Cat. No. | Product name | CAS No. |
DC4210 |
Azilsartan kamedoxomil
Featured
Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. |
863031-24-7 |
DCAPI1469 |
azilsartan
Featured
Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM. |
147403-03-0 |
DC9670 |
BIBS39
Featured
BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist. |
133085-33-3 |
DC9185 |
Candesartan cilexetil
Featured
Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. |
145040-37-5 |
DC9142 |
Candesartan
Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM. |
139481-59-7 |
DC10869 |
Olodanrigan(EMA401)
Featured
EMA401(Olodanrigan) is a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. |
1316755-16-4 |
DCAPI1419 |
Losartan
Losartan is a potent, non peptide antagonist of the angiotensin II receptor type 1. This receptor initiates a signal cascade that causes vasoconstriction. Antagonism of this receptor in turn causes vasodilation by blocking the signal from angiotensin II. |
114798-26-4 |
DC9153 |
Losartan Potassium
Featured
Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. |
124750-99-8 |
DCAPI1464 |
Olmesartan
Olmesartan Acid is an angiotensin II receptor antagonist that prevents the binding of angiotensin II, thus preventing vasoconstriction. |
144689-24-7 |
DC9179 |
Olmesartan MedoxoMil
Olmesartan medoxomil(Olmetec; Benicar; CS 866) is an angiotensin II receptor antagonist which is used as an anti-hypertensive. |
144689-63-4 |
DC7224 |
PD 123319
Featured
PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM. |
136676-91-0 |
DCAPI1452 |
Valsartan
Valsartan is a nonpeptide angiotensin II AT1-receptor antagonist with an IC50 ranging from 39.5 to 116 μM. This in turn causes blood vessel dilation. |
137862-53-4 |
DC8901 |
Azilsartan medoxomil
Featured
Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension. |
863031-21-4 |
DC28342 |
TD-0212 TFA
TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP. |
1073549-11-7 |
DC28348 |
BMS-248360
BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 displays hypertensive effects. |
254737-87-6 |
DC28820 |
Valsartan Ethyl Ester
Valsartan Ethyl Ester is an impurity of Valsartan. Valsartan is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure. |
1111177-30-0 |
DC29128 |
Angiotensin II (1-4), human TFA
Angiotensin II (1-4), human (TFA) is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca2+ levels. Angiotensin II also acts at the Na+/H+ exchanger in the proximal tubules of the kidney. |
|
DC29138 |
TRV-120027
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment. |
1234510-46-3 |
DC29139 |
TRV-120027 TFA
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment. |
|
DC40540 |
Olmesartan medoxomil impurity C
Olmesartan medoxomil impurity C is an Olmesartan medoxomil impurity. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM. |
879562-26-2 |
DC40552 |
Olmesartan lactone impurity
Olmesartan lactone impurity is a cyclic ester impurity of Olmesartan. Olmesartan is an angiotensin II receptor (AT1R) antagonist and has the potential for high blood pressure study. |
849206-43-5 |
DC40553 |
Dehydro Olmesartan
Dehydro Olmesartan is a derivative of Olmesartan. Olmesartan is an angiotensin II receptor (AT1R) antagonist and has the potential for high blood pressure study. |
172875-98-8 |